Histogen Inc. and Gail K. Naughton, Ph.D. entered into a Confidential Severance Agreement and General Release pursuant to which Dr. Naughton’s employment as the company’s Chief Scientific Officer will end as of May 31, 2021. Dr. Naughton will remain with the Company in an advisory role through May 31, 2023, subject to the discretion of the company to continue such advisory services through this initial term. In connection with Dr. Naughton’s transition, Dr. Naughton entered into a Consulting Agreement, effective as of June 1, 2021, with the company that establishes the terms and compensation associated with her transition and consulting services.